Drug
Recombinant human nerve growth factor clinical trials
Also written rhNGF.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 1
Dompé Farmaceutici S.p.A (10) · Ospedale San Raffaele (1)
Studies
Open first, then newest update. How each study uses recombinant human nerve growth factor is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.CompletedPhase 2Dompé Farmaceutici S.p.ANCT06244316Written as rhNGF 5 μg/mL
- Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy VolunteersCompletedPhase 1Dompé Farmaceutici S.p.ANCT01744704Written as rhNGF 0.5 µg/mL Sentinel
- A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry EyeCompletedPhase 2Dompé Farmaceutici S.p.ANCT03982368Written as rhNGF 20 μg/ml
- Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry EyeCompletedPhase 2Dompé Farmaceutici S.p.ANCT02101281Written as rhNGF 20 µg/mL
- A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive SurgeryCompletedPhase 2Dompé Farmaceutici S.p.ANCT03035864Written as rhNGF
- Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.CompletedPhase 1/2Dompé Farmaceutici S.p.ANCT01756456Written as rhNGF 10 μg/ml
- A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)CompletedPhase 1/2Dompé Farmaceutici S.p.ANCT02110225Written as rhNGF 60 µg/ml eye drops solution
- Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy VolunteersCompletedPhase 1Dompé Farmaceutici S.p.ANCT03836859Written as rhNGF 20μg/mL
- Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NKCompletedPhase 2Dompé Farmaceutici S.p.ANCT02227147Written as rhNGF 20µg/ml
- Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With GlaucomaCompletedPhase 1Dompé Farmaceutici S.p.ANCT02855450Written as rhNGF
- Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular EdemaCompletedPhase 2Ospedale San RaffaeleNCT02609165Written as rhNGF 180 µg/ml eye drops solution